Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Hologic (HOLX) has been making impressive progress in its Breast Health arm, leveraging its strategic expansion efforts to diversify business across the patient continuum of care.

Hologic (HOLX) Gains From New Launches as Macro Concerns Rise

FARGO, N.D. , Sept. 11, 2023 /PRNewswire/ -- Jennifer Meade has been named President of Aldevron, effective September 11 th 2023, as part of a planned leadership transition.

Jennifer Meade Named President at Aldevron

Strength in Breast Health and GYN Surgical drives Hologic's (HOLX) Q3 performance.

Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up

Hologic, Inc. (NASDAQ:HOLX ) Q3 2023 Earnings Conference Call July 31, 2023 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Michael Matson - Needham & Company Jack Meehan - Nephron Research Vijay Kumar - Evercore ISI Timothy Daley - Wells Fargo Tejas Savant - Morgan Stanley Puneet Souda - Leerink Partners Anthony Petrone - Mizuho Group Ryan Zimmerman - BTIG Andrew Cooper - Raymond James Andrew Brackmann - William Blair Elizabeth Garcia - UBS Operator Good afternoon, and welcome to the Hologic's Third Quarter Fiscal 2023 Earnings Conference Call. My name is Cynthia, and I am your operator for today's call.

Hologic, Inc. (HOLX) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Hologic (HOLX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Hologic (HOLX) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.95 per share a year ago.

Hologic (HOLX) Tops Q3 Earnings and Revenue Estimates

Shares of Hologic Inc. HOLX, -1.57% dropped more than 3% in the aftermarket Monday after the medical technology company topped Wall Street estimates for its fiscal third quarter and tweaked its guidance for the fiscal year and for the fiscal fourth quarter. Hologic lost $40.5 million, or 16 cents a share, in the quarter, versus earnings of $228.4 million, or 90 cents a share, in the year-ago period.

Hologic stock falls nearly 4% after company's revenue drop on lower COVID-related sales

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal third quarter ended July 1, 2023. “Hologic again delivered solid, diversified growth in our fiscal third quarter, excluding the impact of COVID,” said Steve MacMillan, the Company's chairman, president and chief executive officer. “Our results once again highlight that Hologic's transformation and post-pandemic performance is durable. Our business is operating from a.

Hologic Announces Financial Results for Third Quarter of Fiscal 2023

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Hologic (HOLX) to Report a Decline in Earnings: What to Look Out for

Hologic's (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.

Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings

Albany International

Toll Brothers

Diving into a world where an analyst picks stocks may feel like exploring a complex maze. These analysts, akin to dedicated scholars of the stock market, offer their expertise to investors in pointing out potential pathways for investors.

3 Top Analyst Picks Worth Your Attention Now

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (877) 400-0505 (in the United States and Canada) or +1 (773) 305-6865 (for international callers) and referencing.

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2023 on Monday, July 31, 2023

Hologic continues to present with attractive business economics and robust fundamentals ex-Covid. There are additional critical factors to consider, including positive sentiment and price studies. Investors look to be bullish on HOLX based on the culmination of studies presented in this report.

Hologic: Additional Critical Factors Forming Bullish Thesis, Reiterate Buy

Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.

Hologic (HOLX) Gains From Core Businesses' Growth, Innovation

Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.

Here's Why You Should Invest in Hologic (HOLX) Stock Now

The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.

Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Why Is Hologic (HOLX) Down 6.3% Since Last Earnings Report?

June has been a strong month for this stock.

Stocks This Week: Buy Hologic

Integer Holdings

Masimo

The Zacks Medical - Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most.

3 Medical Instruments Stocks to Buy Amid Industry Challenges

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #FDA--Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay.

Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo

MARLBOROUGH, Mass. , May 16, 2023 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced a new partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.

Hologic Announces Partnership with NFL Rookie Kelee Ringo and Family

Arch Capital

Archer-Daniels-Midland Company

Axon Enterprise

Corteva Inc

Caesars Entertainment

Gartner

Lamb Weston Hlds

Royal Caribbean Cruises

T-Mobile US

Corporate profits in the S&P 500 are coming in strong. So strong, in fact, that some keep blowing away even the analysts' expectations.

10 Companies Are Doing So Well Even Analysts Are Amazed

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #bofaconference--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the BofA Securities 2023 Healthcare Conference in Las Vegas, NV on Tuesday, May 9 at 2:20 p.m. Pacific Time. The presentation will be webcast live and may be accessed through a link on the investors section of Hologic's website at http://investors.hologic.com. The webcast will be available for 30 days following the event. About Hologic Hologic, Inc. is an innovative medical technol.

News for Hologic Stock (HOLX)